Outsourcing Pharma

APRIL 7, 2022

Experts from the Decentralized Trials and Research Alliance and Rafael Pharmaceuticals discuss progress and possibilities during Clinical Development Advances.

Clinical Development 75

Clinical Development Development Trials Research 75

Pharma Mirror

JUNE 23, 2021

Vectura Group plc, an industry leading inhalation CDMO, today announced it has signed an agreement with Incannex Healthcare Limited, an Australian cannabinoid medicines development company, to provide pre-clinical development services for IHL-216A, Incannex’s proprietary inhaled drug product for the treatment of traumatic brain injury (TBI).

Clinical Development 130

Clinical Development Development Drugs Medicine 130

Medical Xpress

APRIL 26, 2023

A successful gene therapy trialed at Michigan State University in dogs with an inherited eye disease is ready to be developed for clinical use in human patients with a rare condition called retinitis pigmentosa.

Gene Therapy 133

Gene Therapy Clinical Development Gene Development 133

Scienmag

JULY 19, 2022

July 19, 2022, New York—Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI) driven drug discovery company, has appointed Dr. Sujata Rao as Senior Vice President (SVP) with responsibility for the global clinical development strategy of Insilico Medicine’s therapeutic programs.

Clinical Development 83

Clinical Development Medicine Development Drugs 83

Drug Discovery World

MARCH 8, 2023

The post €25 million to support clinical developments against Long Covid appeared first on Drug Discovery World (DDW). This transaction complements the cycle of Covid-19 related syndromes tackled by innovative European biotech companies that benefited from EIB support through its venture debt programme”.

Clinical Development 52

Clinical Development Development Vaccination Vaccine 52

BioSpace

JULY 22, 2021

Shares of Adverum Biotechnologies plunged more than 20% in premarket trading after the company announced it was revising its clinical development plan for investigational gene therapy candidate ADVM-022 based on safety concerns in patients with diabetic macular edema (DME).

Gene Therapy 98

Gene Therapy Clinical Development Gene Development 98

Pharma Mirror

FEBRUARY 25, 2022

This joint service offering, DRIVE™-Biologics, will leverage Abzena’s strength in design and developability, and cell line development through to commercial manufacturing.

Clinical Development 130

Clinical Development Development Medicine Drugs 130

BioSpace

SEPTEMBER 15, 2020

Clinical-stage biopharmaceutical firm ESCAPE Bio has snagged a $73 million crossover financing deal, led by Wellington Management Company, which will help advance the company’s two clinical development programs of precision neurology medicines for patients with genetic neurodegeneration.

Clinical Development 95

Clinical Development Genetics Development Medicine 95

Pharmaceutical Technology

MARCH 23, 2023

We look forward to advancing BHV-8000 into clinical development and uncovering the potential of neuroimmunomodulation for severe neurological disorders in desperate need of novel treatment options.” Hangzhou Highlightll will also receive up to $950m in development and commercial milestone payments and tiered royalties.

Licensing 263

Licensing Licensing Clinical Development Trials 263

Pharmaceutical Technology

APRIL 3, 2023

The agreement allows Ablaze to clinically develop and commercialise the drug in Greater China. It is based on RayzeBio’s specialisation in targeted radiotherapy (TRT) discovery and Ablaze’s know-how in therapeutic product clinical development, as well as on the radiopharmaceutical infrastructure in China.

Drugs 246

Drugs Development Clinical Development Medicine 246

Pharmaceutical Technology

APRIL 21, 2023

Biotechnology company Enveda Biosciences has raised $51m in equity financing in a Series B1 round to advance several drug candidates to clinical development. Enveda Biosciences intends to use the additional financing to advance several candidates derived from its drug discovery platform to clinical development in 2023 and 2024.

Clinical Development 147

Clinical Development Drugs Medicine Development 147

Pharmaceutical Technology

MAY 31, 2023

Betta chairman and CEO Lieming Ding stated: “The collaboration will further expand Betta’s product pipeline and improve the productivity of the company’s research and development from discovery to clinical development and to commercialisation.”

Bioavailability 130

Bioavailability In-Vitro In-Vivo Clinical Development 130

The Pharma Data

DECEMBER 14, 2020

AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. About AlgoTherapeutix AlgoTx was founded in 2018 by Stéphane Thiroloix and Olivier Bohuon to develop topical treatments for complex pain and was incubated by Paris Biotech Santé. Source link.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

Pharmaceutical Technology

APRIL 13, 2023

Fusion stated that FPI-2068 will become the first programme to enter clinical development under its collaboration agreement with AstraZeneca. It will conduct the Phase I trial, while AstraZeneca will handle the subsequent clinical development of FPI-2068.

Clinical Development 147

Clinical Development Antibody Drugs Trials 147

Pharmaceutical Technology

MAY 12, 2023

The companies will undertake discovery and pre-clinical development work to identify brain-penetrant biologic therapeutics using JCR Pharmaceuticals’ J-brain cargo, a blood-brain barrier-penetrating technology. JCR Pharmaceuticals will retain the commercialisation rights of the candidates in Japan.

Clinical Development 130

Clinical Development Development Research 130

BioTech 365

MAY 17, 2021

Brii Biosciences Provides Update on Strategic Clinical Development Progress Brii Biosciences Provides Update on Strategic Clinical Development Progress Company received U.S.

Clinical Development 52

Clinical Development Development Drugs 52

BioPharma Reporter

MARCH 3, 2021

The number of advanced therapy medicinal product (ATMP) clinical trials in the UK continues to increase year on year with 154 ongoing trials observed in 2020, demonstrating the appeal of that market for the clinical development of ATMPs, shows a new report.

Clinical Development 52

Clinical Development Clinical Trials Clinical Trials Development 52

BioTech 365

JANUARY 4, 2022

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE – Company plans to focus development of Zygel™ in FXS, ASD and 22q – – Company … Continue reading →

Clinical Development 40

Clinical Development Development 40

The Pharma Data

MARCH 23, 2022

Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. He also led the expansion of Merck’s research and development in China and Japan. “It Baynes will be succeeded by Dr. Eliav Barr, senior vice president, Global Clinical Development.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

BioTech 365

NOVEMBER 10, 2021

Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates Announced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease … Continue reading →

Clinical Development 52

Clinical Development Development 52

BioTech 365

NOVEMBER 12, 2021

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments First Patients Dosed in Camsirubicin Phase 1b Clinical Trial in U.S.Validive® Phase 2b/3 VOICE Trial Cleared … Continue reading →

Clinical Development 40

Clinical Development Clinical Trials Clinical Trials Development 40

BioTech 365

JULY 1, 2021

SQZ Biotechnologies Strengthens Board with Global Commercial and Clinical Development Experience SQZ Biotechnologies Strengthens Board with Global Commercial and Clinical Development Experience Bernard Coulie, M.D., and Patrick Vink, M.D. Join Board of Directors WATERTOWN, Mass.–(BUSINESS

Clinical Development 52

Clinical Development Development 52

Pharmaceutical Technology

MAY 22, 2023

“As the world’s first humanised IgG4-κ monoclonal antibody targeting IL-17RB, SM17 has made satisfactory progress in clinical research under the active promotion of the company. It is expected that this new treatment option will benefit more Chinese patients in the future and bring a promising treatment for severe asthma patients.”

Clinical Trials 273

Clinical Trials Clinical Trials Antibody Immune Response 273

BioPharma Reporter

OCTOBER 11, 2021

Samsung Biologics and Enzolytics have entered into a strategic CDMO partnership agreement targeting monoclonal antibody production.

Clinical Development 145

Clinical Development Antibody Development Production 145

BioTech 365

AUGUST 31, 2021

Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant Elinzanetant is a non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause WHIPPANY, … Continue (..)

Clinical Development 52

Clinical Development Hormones Development Production 52

Pharmaceutical Technology

MAY 17, 2023

The company will also be entitled to receive potential development and regulatory milestone payments, along with royalty payments. It will also handle the IND-enabling toxicology studies while Chinook Therapeutics will undertake the clinical development and commercialisation activities of the therapy.

Protein 246

Protein RNA Development Medicine 246

BioTech 365

AUGUST 10, 2021

Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update Announced positive topline results from the EQUATE study of itolizumab in first-line treatment of acute graft-versus-host … Continue reading →

Clinical Development 52

Clinical Development Development 52

BioTech 365

FEBRUARY 3, 2022

iOmx Therapeutics Appoints Dr. Murray Yule as CMO to Lead Clinical Development Lead program IMT-07 addressing a novel … Continue reading → DGAP-News: iOmx Therapeutics AG / Key word(s): Personnel 03.02.2022 / 10:00 The issuer is solely responsible for the content of this announcement.

Clinical Development 40

Clinical Development Development 40

BioTech 365

DECEMBER 15, 2020

AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01 AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01 PARIS–(BUSINESS WIRE)–France-based biotechnology company AlgoTherapeutix, the developer of an innovative topical treatment for chemotherapy-induced peripheral neuropathy (..)

Clinical Development 52

Clinical Development Development 52

BioTech 365

JANUARY 6, 2022

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205 Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205 Response to pre-IND briefing package supports pathway to initiating a Phase 1 … Continue reading →

Clinical Development 40

Clinical Development Development Packaging Packaging 40

BioTech 365

NOVEMBER 11, 2021

ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif.,

Clinical Development 40

Clinical Development Development 40

Pharmaceutical Technology

APRIL 25, 2023

FAP-2286 marks the first peptide-targeted radioligand therapy aiming at FAP to enter clinical development, along with the respective imaging agent. The therapy candidate is currently under evaluation in the Phase l LuMIERE clinical trial.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

Pharmaceutical Technology

MAY 9, 2023

Under the clinical development strategy, FibroGen will continue the work of Fortis Therapeutics to develop a PET-based biomarker using a radiolabeled version of the targeting antibody (PET46) for selecting patients. FOR46 is a natural fit with our research and development capabilities and expertise.

Drugs 130

Drugs Antibody Clinical Development Gene 130

BioTech 365

SEPTEMBER 30, 2020

Press Release 30 September 2020 Immunicum AB Announces Update on Corporate and Clinical Development Strategy Immunicum AB (publ: IMMU.ST) announced today an update on the Company’s corporate and clinical development strategy. The strategy will be presented by members of the … Continue reading →

Clinical Development 40

Clinical Development Development 40

BioTech 365

DECEMBER 13, 2021

Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development Press Release Nicox Appoints Doug Hubatsch as new Chief Scientific … Continue reading →

Clinical Development 40

Clinical Development Development 40

Pharmaceutical Technology

MAY 17, 2023

TAK-755 is the first and only treatment in clinical development that provides targeted replacement of ADAMTS13, addressing the underlying cause of the disease. “We We continue to be encouraged by the data and are working closely with the US FDA and other global regulatory bodies with the goal to bring this treatment to patients.”

Genetics 242

Genetics Clinical Development Drugs Trials 242

BioTech 365

JULY 26, 2021

Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven Lantern will reacquire global rights to Irofulven and assume full authority to … Continue reading →

Clinical Development 40

Clinical Development Development 40